Used in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), darolutamide works by blocking the androgen receptor signaling pathway, which helps slow tumor growth. It is prescribed to reduce the risk of metastasis in patients with rising prostate-specific antigen (PSA) levels despite testosterone suppression. Due to its distinct molecular structure, it has limited blood-brain barrier penetration, potentially reducing central nervous system-related side effects compared to other agents in its class. It is typically administered orally in combination with androgen deprivation therapy.